Agrawal, A.; Srivastava, M.V.P.; Bhatia, R.; Goyal, V.; Singh, M.B.; Vishnu, V.Y.; Prabhakar, A.
A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study. Brain Sci. 2023, 13, 1249.
https://doi.org/10.3390/brainsci13091249
AMA Style
Agrawal A, Srivastava MVP, Bhatia R, Goyal V, Singh MB, Vishnu VY, Prabhakar A.
A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study. Brain Sciences. 2023; 13(9):1249.
https://doi.org/10.3390/brainsci13091249
Chicago/Turabian Style
Agrawal, Arpit, M. V. Padma Srivastava, Rohit Bhatia, Vinay Goyal, Mamta Bhushan Singh, Venugopalan Y. Vishnu, and Anuj Prabhakar.
2023. "A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study" Brain Sciences 13, no. 9: 1249.
https://doi.org/10.3390/brainsci13091249
APA Style
Agrawal, A., Srivastava, M. V. P., Bhatia, R., Goyal, V., Singh, M. B., Vishnu, V. Y., & Prabhakar, A.
(2023). A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study. Brain Sciences, 13(9), 1249.
https://doi.org/10.3390/brainsci13091249
